Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hong Kong criminalizes CBD, ranking it alongside heroin and cocaine
https://www.cbsnews.com/news/hong-kong-cbd-criminalized-ranks-with-heroin-cocaine/ $TOKE
Hong Kong criminalizes CBD, ranking it alongside heroin and cocaine
https://www.cbsnews.com/news/hong-kong-cbd-criminalized-ranks-with-heroin-cocaine/ $TOKE
Profits are tough to garner when competing with Black Markets......................
https://www.cnbc.com/2022/12/23/marijuana-black-market-undercuts-legal-business.html
Best wishes,
OAG Tom
Profits are not easy when competing with the Black Market.......................
https://www.cnbc.com/2022/12/23/marijuana-black-market-undercuts-legal-business.html
OAG Tom
just 1 executive order away from bouncing into the $ 200.00 range . maybe much higher .
TOKE is starting to show some accumulation of shares here in the low $8s. It's been building slowly since the end of June - barely enough to show on a 1 Year chart.
https://schrts.co/NcHbSagF
Best wishes,
OAG
The last 12 months haven't been pretty. Maybe the Shorties will move on to something else.
OAG
the fields O' green drowning in a red tsunami . I will buy in July . maybe below $ 5.00 .
It's been a good week so far.
OAG
TOKE bottoming and starting a new upward trend would be nice.
I've been accumulating shares as it's dropped.
Best wishes,
OAG
looking forward to seeing how high this will spike when the green tsunami rolls in . 2 million in the float ? #1 holding is TLRY ? get ready .
It's been a year since this thread was started. In that time TOKE has nearly doubled and then halved. It will be interesting to see how TOKE develops over time. I've been looking at their holdings as well.
My position started at $22.58 in February of 2021 so it's not been the best of times so far, down 45% on initial share cost. I've averaged down on share price several times and now I need to wait for some sort of recovery.
Accumulation/Distribution line has been almost continuously on the Distribution side while I've been accumulating. I guess someone has to provide liquidity for those who've been selling!
Best wishes,
OAG Tom
just received the dividend from TOKE @ 6%,time to add more.
$TOKE has been moving up nice and steady the last month and a half or so. Full legalization or the appearance of it will keep this heading up.
$TOKE it up!
Cambria Cannabis ETF (TOKE)
Summary Prospectus
September 1, 2020
Listed on CBOE BZX Exchange, Inc.
Before you invest, you may want to review the Fund’s Prospectus, which contains more information about the Fund and its
risks. You can find the Fund’s Prospectus, Statement of Additional Information, shareholder reports, and other information
about the Fund online at www.cambriafunds.com/toke. You can also get this information at no cost by calling 855-ETF-INFO
(383-4636) or by sending an e-mail request to info@cambriafunds.com. The Fund’s Prospectus and Statement of Additional
Information, both dated September 1, 2020, as each may be amended or supplemented, are incorporated by reference into this
Summary Prospectus.
Beginning on January 1, 2021, as permitted by regulations adopted by the SEC, paper copies of the Fund’s shareholder reports
will no longer be sent by mail, unless you specifically request paper copies of the reports from your financial intermediary
(such as a broker-dealer or bank). Instead, the reports will be available on the Fund’s website (www.cambriafunds.com), and
you will be notified by mail each time a report is posted and provided with a website link to access the report.
If you already elected to receive shareholder reports electronically, you will not be affected by this change and you need not
take any action. You may elect to receive shareholder reports and other communications from the Fund electronically anytime
by contacting your financial intermediary.
You may elect to receive all future reports in paper free of charge. Please contact your financial intermediary to request to
continue receiving paper copies of your shareholder reports. Your election to receive reports in paper will apply to all funds
held in your account.
FUND SUMMARY
Cambria Cannabis ETF
Investment Objective
The Fund seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis
industry.
Fees and Expenses
This table describes the fees and expenses that you may pay if you buy, hold and sell Shares. You may pay other fees, such
as brokerage commissions and other fees to financial intermediaries, which are not reflected in the table and example below.
Annual Fund Operating Expenses (EXPENSES THAT YOU PAY EACH YEAR AS A PERCENTAGE OF THE
VALUE OF YOUR INVESTMENT)
Management Fee:......................................................................................................................................................... 0.59%
Distribution and/or Service (12b-1) fees: .................................................................................................................... 0.00%
Other Expenses: ........................................................................................................................................................... 0.00%
Total Annual Fund Operating Expenses: ..................................................................................................................... 0.59%
Less Fee Waiver: .......................................................................................................................................................... (0.17)%
Total Annual Fund Operating Expenses After Fee Waiver:* ....................................................................................... 0.42%
* The Fund’s investment adviser has agreed to waive 17 basis points (0.17%) of its management fees for the Fund until at least
August 31, 2021. This agreement may be terminated only by, or with the consent of, the Trust’s Board of Trustees.
Example
The following example is intended to help you compare the cost of investing in the Fund with the cost of investing in other
funds. The example assumes that you invest $10,000 in the Fund for the time periods indicated and then redeem all of your
Shares at the end of those periods. The example also assumes that the Fund provides a return of 5% a year and that operating
expenses remain the same. The example does not reflect any brokerage commissions that you may pay on purchases and sales
of Shares.
Although your actual costs may be higher or lower, based on these assumptions, your costs would be:
One Year: Three Years: Five Years: Ten Years:
$43 $189 $329 $738
Portfolio Turnover
The Fund may pay transaction costs, including commissions, when it buys and sells securities (or “turns over” its portfolio).
A higher portfolio turnover rate may indicate higher transaction costs and may result in higher taxes when Shares are held in a
taxable account. These costs, which are not reflected in the annual fund operating expenses or in the example, affect the Fund’s
performance. For the fiscal period July 24, 2019 (commencement of operations) through April 30, 2020, the Fund’s portfolio
turnover rate was 4% of the average value of its portfolio.
Principal Investment Strategies
The Fund seeks to achieve its investment objective by investing, under normal market conditions, primarily in global equity
securities that provide a broad exposure to the cannabis industry. Equity securities that provide broad exposure to the cannabis
industry include companies that (i) engage in or support the legal production, cultivation, and/or sale of cannabis, including
marijuana and hemp, such as certain agrobusiness, biotechnology, life sciences, pharmaceutical, retail, finance, and real estate
companies, (ii) perform lawful research as to the medical and pharmaceutical applications of marijuana and cannabis extracts,
including cannabinoids, or (iii) produce and develop devices, goods, and equipment related to the cannabis industry, including
hemp and its legal derivatives (collectively, “Cannabis Companies”).
As the cannabis industry matures over time, Cambria
Investment Management, L.P., the Fund’s investment adviser (“Cambria”), expects that the industry will grow and crossover
with other established industries such as tobacco, food, alcohol, medicine, tourism, and personal care, and the definition of
Cannabis Company will evolve as new business lines and products develop. Under the Farm Bill of 2018, hemp is defined as
being derived from cannabis plants and plant parts that contain 0.3% or less of tetrahydrocannabinol (THC), the psychoactive
agent found in marijuana, in their leaves and flowering heads. Hemp is commonly used to produce textiles, paper products,
rope, and construction materials, and legal derivatives of hemp, such as hemp seeds, hemp seed oil and hemp seed protein, can
be used in food products, cosmetics, plastics, and biofuel.
Cannabinoids, such as THC and cannabidiol (CBD), are chemical
compounds found in the cannabis plant that may be used in lawful research and the development of prescription drugs.
To be identified as a Cannabis Company, Cambria must determine that a company derives a significant portion (i.e., at least
50%) of its revenue or profits from the legal sale, cultivation, production, or provision of cannabis-related products, services,
or research. The Fund will only invest in publicly-traded Cannabis Companies that operate in a jurisdiction where the Cannabis
Companies’ cannabis-related business activities are legal under the national and local laws of the relevant jurisdiction, including
U.S. federal and state laws. Further, the Fund will only invest in Cannabis Companies listed and traded on a national securities
exchange that requires compliance with all laws, rules and regulations applicable to their business, including U.S. federal
law.
Accordingly, the Fund does not currently (directly or indirectly) invest in Cannabis Companies located in the U.S. if
their cannabis-related business activities are illegal under U.S. federal law, even if such activities are legal under state law. If
U.S. federal law changes in the future and these cannabis-related business activities become legal at the federal level, the Fund
will begin investing in these U.S.-listed Cannabis Companies in accordance with the Fund’s investment objective and principal
investment strategy.
Under normal market conditions, at least 80% of the value of the Fund’s net assets (plus borrowings for investment purposes)
will be invested in Cannabis Companies. The Fund generally expects to invest in Cannabis Companies across a broad market
capitalization spectrum of micro-, small-, and mid-capitalization stocks. While the Fund will target investing in approximately
20 to 50 of the top Cannabis Companies based on Cambria’s determination as to their exposure to the cannabis industry, the
quantity of holdings in the Fund will be based on a number of factors, including the asset size of the Fund and the number
of companies that satisfy Cambria’s quantitative measurements at any one time.
Filters will be implemented to screen for
companies that pass various market capitalization, and liquidity requirements. The Fund expects to concentrate (hold more
than 25% of) its assets in Cannabis Companies domiciled or principally traded in Canada and invest a significant portion of
its assets in Cannabis Companies domiciled or principally traded in Australia, Europe or Asia.
The Fund’s portfolio will be rebalanced periodically, but no less frequently than annually, to meet Cambria’s internal target
allocations, which are developed pursuant to Cambria’s quantitative strategy. If, after acquiring a Cannabis Company’s securities,
Cambria identifies or becomes aware that the company no longer meets the Fund’s definition of Cannabis Companies, the
Fund will promptly sell that position. The Fund may sell a security when Cambria believes that the security is overvalued or
better investment opportunities are available, to invest in cash and cash equivalents, or to meet redemptions.
Principal Risks
An investment in the Fund involves risk. The Fund’s principal risks are presented below in alphabetical order to facilitate
investors’ ability to find particular risks and compare them with the risks of other funds. Each risk summarized below is
considered a “principal risk” of investing in the Fund, regardless of the order in which it appears. Some or all of these risks
may adversely affect the Fund’s net asset value per share (“NAV”), trading price, yield, total return, and/or ability to meet its
objective. There is no assurance that the Fund will achieve its investment objective. An investor may lose money by investing
in the Fund. For more information about the risks of investing in the Fund, see the sections titled “Additional Information
About the Funds’ Risks” and “Additional Non-Principal Risk Information.”
Cannabis Industry Risk. Cannabis Companies are subject to various laws and regulations that may differ at the local and
federal level. These laws and regulations may significantly affect a Cannabis Company’s ability to secure financing, impact the
market for cannabis industry sales and services, and set limitations on marijuana use, production, transportation, and storage.
Cannabis Companies may also be required to secure permits and authorizations from government agencies to cultivate or
research marijuana. In addition, Cannabis Companies are subject to the risks associated with the agricultural, biotechnology,
and pharmaceutical industries. The Fund only invests in publicly-traded Cannabis Companies primarily listed and traded on a
national securities exchange that operates in a jurisdiction where the Cannabis Companies’ cannabis-related business activities
are legal under the national and local laws of the relevant jurisdiction, including U.S. federal and state laws.
U.S. Regulation of Marijuana. Although the medical use of marijuana is legal in more than half of the states as
well as the District of Columbia and non-medical use of marijuana is legal in ten states and the District of Columbia,
the possession and use of marijuana remains illegal under U.S. federal law.
In addition, pronouncements from the
current Administration suggest the Department of Justice (“DOJ”) may push back against states where marijuana use
and possession is legal, step up the enforcement of federal marijuana laws and the prosecution of nonviolent federal
drug crimes, and seek to overturn the Rohrabacher-Blumenauer amendment to the federal spending bill. Such actions
by the DOJ could produce a chilling effect on the industry’s growth and discourage banks from servicing Cannabis
Companies and/or serving as custodian for this Fund. This conflict between the regulation of marijuana under federal
and state law creates volatility and risk for all Cannabis Companies. In particular, the stepped up enforcement of
marijuana laws by the federal government would adversely affect the value of the Fund’s U.S. investments, if any,
as well as the Fund’s future ability to invest in Cannabis Companies primarily listed and traded on a U.S. national
securities exchange and/or engaged in cannabis-related businesses in the U.S. Cannabis Companies that engage in
medical or pharmaceutical research or the production and distribution of controlled substances such as marijuana
must be registered with the Drug Enforcement Administration (“DEA”) to perform such activities. Further, the DEA
has no obligation to ever issue such registration to cannabis or marijuana products.
Non-U.S. Regulation of Marijuana. Laws and regulations related to the possession, use (medical or recreational),
sale, transport and cultivation of marijuana vary throughout the world. These laws and regulations are subject to
change and may have a significant impact on the operations of a Cannabis Company.
Such operations may be legal
under current law, but may be illegal in the future if the applicable law changes to prohibit marijuana-related activities
vital to the company’s business.
Sector Risk. To the extent that the Fund invests a significant portion of its assets in a particular economic sector, the Fund may
be susceptible to loss due to adverse occurrences affecting that sector.
Consumer Staples Sector Risk. The consumer staples sector includes, for example, food and drug retail and
companies whose primary lines of business are food, beverage and other household items, including agricultural
products.
This sector can be significantly affected by, among other things, changes in price and availability of
underlying commodities, rising energy prices and global and economic conditions.
Health Care Sector Risk.
The health care sector includes, for example, biotechnology, pharmaceutical, health care
facilities, and health care equipment and supply companies. This sector can be significantly affected by, among other
things, lapsing patent protection, technological developments that make drugs obsolete, government regulation, price
controls, and approvals for drugs.
Cyber Security Risk.
The Fund, and its service providers, may be susceptible to operational and information security risks
resulting from a breach in cyber security, including cyber-attacks. A breach in cyber security, intentional or unintentional,
may adversely impact the Fund in many ways, including, but not limited to, disruption of the Fund’s operational capacity, loss
of proprietary information, theft or corruption of data, denial-of-service attacks on websites or network resources, and the
unauthorized release of confidential information. Cyber-attacks affecting the Fund’s third-party service providers, including
Cambria, the custodian, and the transfer agent, market makers, Authorized Participants, or the issuers of securities in which the
Fund invests may subject the Fund to many of the same risks associated with direct cyber security breaches.
Emerging Markets Risk.
Emerging market investments are subject to the same risks as foreign investments and to additional
risks due to greater political and economic uncertainties as well as a relative lack of information about issuers in such markets.
Securities of emerging market issuers may become illiquid and be subject to volatility and high transaction costs.
Equity Investing Risk. The values of equity securities could decline generally or could underperform other investments due
to factors affecting a specific issuer, market or securities markets generally.
Foreign Investment Risk.
Returns on investments in foreign securities could be more volatile than, or trail the returns on,
investments in U.S. securities. Exposures to foreign securities entail special risks, including risks due to: (i) differences in
information available about foreign issuers; (ii) differences in investor protection standards in other jurisdictions; (iii) capital
controls risks, including the risk of a foreign jurisdiction imposing restrictions on the ability to repatriate or transfer currency
or other assets; (iv) political, diplomatic and economic risks; (v) regulatory risks; and (vi) foreign market and trading risks,
including the costs of trading and risks of settlement in foreign jurisdictions. In addition, the Fund’s investments in securities
denominated in other currencies could decline due to changes in local currency relative to the value of the U.S. dollar, which
may affect the Fund’s returns.
Geographic Investment Risk.
To the extent the Fund invests a significant portion of its assets in the securities of companies
of a single country or region, it is more likely to be impacted by events or conditions affecting that country or region. The Fund
expects to invest a significant portion of its assets in the securities of companies in Canada and the United Kingdom.
Canada Risk.
Changes to the U.S. economy may significantly affect the Canadian economy because the U.S. is
Canada’s largest trading partner and foreign investor. The economy of Canada is also heavily dependent on the
demand for natural resources and agricultural products. Accordingly, a change in the supply and demand of these
resources, both in Canada and worldwide, can have a significant effect on Canadian market performance. Conditions
that weaken demand for its products worldwide could have a negative impact on the Canadian economy as a whole.
United Kingdom Risk.
The United Kingdom trades heavily with other European countries and the United States and
may be impacted by changes to the economic health of their key trading partners. The United Kingdom also relies
heavily on the export of financial services. Accordingly, a downturn in the financial services sector may have an
adverse impact on the United Kingdom’s economy. In January 2020, the United Kingdom formally exited the EU. It
remains unclear how withdrawal negotiations will be concluded and what the potential consequences of Brexit may
be, but the economies of the UK and Europe, as well as the broader global economy, could be significantly impacted
by Brexit, which may result in lower economic growth and increased volatility and illiquidity across global markets.
International Closed-Market Trading Risk.
Because the Fund’s investments may be traded in markets that are closed when
the Exchange is open, there are likely to be deviations between the current pricing of an underlying investment and stale
investment pricing (i.e., the last quote from its closed foreign market), resulting in premiums or discounts to NAV that may be
greater than those experienced by other ETFs.
Investment Risk.
An investment in the Fund is not a deposit of a bank and is not insured or guaranteed by the Federal Deposit
Insurance Corporation or any other government agency. When you sell your Shares, they could be worth less than what you
paid for them.
Management Risk.
The Fund is actively managed using proprietary investment strategies and processes. There can be no
guarantee that these strategies and processes will be successful or that the Fund will achieve its investment objective.
Market Events Risk.
Turbulence in the financial markets, reduced liquidity in the equity markets, and/or the advent of
certain economic or political events, including global events such as war, acts of terrorism or a public health crisis, may
negatively affect issuers, which could have an adverse effect on the Fund. In addition, there is a risk that policy changes by
the U.S. Government, Federal Reserve and/or other government actors, such as increasing interest rates, could cause increased
volatility in financial markets and higher levels of Fund redemptions, which could have a negative impact on the Fund.
Recent Events. The respiratory illness COVID-19 caused by a novel coronavirus has resulted in a global pandemic
and major disruption to economies and markets around the world, including the United States. Financial markets have
experienced extreme volatility and severe losses, and trading in many instruments has been disrupted. Liquidity for
many instruments has been greatly reduced for periods of time. Some interest rates are very low and in some cases
yields are negative. Some sectors of the economy and individual issuers have experienced particularly large losses.
These circumstances may continue for an extended period of time, and may continue to affect adversely the value and
liquidity of the Fund’s investments.
Micro Capitalization Company Risk.
In addition to the risks associated with investing in small and medium capitalization companies, set forth below, micro capitalization companies are more vulnerable to adverse economic events and poor business
conditions than larger, more established companies. The earnings and revenue of micro capitalization companies tend to be
less predictable, and their securities are generally less liquid and subject to greater and more unpredictable price changes.
Premium-Discount Risk. The Shares may trade above (premium) or below (discount) their net asset value (or “NAV”). The
market prices of Shares will generally fluctuate in accordance with changes in NAV as well as the relative supply of, and
demand for, Shares on the Exchange. This risk is heightened in times of market volatility or periods of steep market declines.
Quantitative Security Selection Risk.
Cambria uses quantitative techniques to generate investment decisions and its processes
and stock selection, and the Fund may not perform as intended if it relies on erroneous or outdated data from one or more third
parties. Errors in data used in the quantitative model may occur from time to time and may not be identified and/or corrected
before having an adverse impact on the Fund and its shareholders.
Secondary Market Trading Risk.
Investors buying or selling Shares in the secondary market may pay brokerage commissions
or other charges, which may be a significant proportional cost for investors seeking to buy or sell relatively small amounts of
Shares. In addition, secondary market investors will also incur a bid/ask spread, which varies over time for Shares based on
trading volume and market liquidity and is generally higher if Shares have little trading volume and market liquidity. Although
the Shares are listed on the Exchange, there can be no assurance that an active or liquid trading market for them will develop or
be maintained. In stressed market conditions, the liquidity of Shares may begin to mirror the liquidity of the Fund’s underlying
portfolio holdings, which can be significantly less liquid than Shares. In addition, trading in Shares on the Exchange may be
halted.
Small and Medium Capitalization Company Risk.
Investing in securities of small and medium capitalization companies
involves greater risk than customarily is associated with investing in larger, more established companies. These companies’
securities may be more volatile and less liquid than those of more established companies, and they may be more sensitive to
market conditions.
Performance
Performance information will be available in the Prospectus after the Fund has been in operation for one full calendar year.
When provided, the information will provide some indication of the risks of investing in the Fund by showing how the
Fund’s average annual returns compare with a broad measure of market performance. As always, please note that the Fund’s
past performance (before and after taxes) does not necessarily indicate how the Fund will perform in the future. Updated
performance will be available at www.cambriafunds.com.
Investment Adviser
Cambria Investment Management, L.P. serves as the investment adviser of the Fund.
Portfolio Manager
Mebane T. Faber is the portfolio manager for the Fund and has managed the Fund since its inception in July 2019.
Purchase and Sale of Fund Shares
Individual Shares are listed on a national securities exchange and may only be purchased and sold in the secondary market
through a broker-dealer at a market price. Because Shares trade at market prices rather than NAV, Shares may trade at a
price greater than NAV (at a “premium”) or less than NAV (at a “discount”). An investor may incur costs attributable to the
difference between the highest price a buyer is willing to pay to purchase Shares (bid) and the lowest price a seller is willing
to accept for Shares (ask) when buying and selling Shares in the secondary market (the “bid/ask spread”). Recent information
regarding the Fund, including its NAV, market price, premiums and discounts, and bid/ask spreads, is available on the Fund’s
website at www.cambriafunds.com.
Tax Information
Distributions you receive from the Fund are generally taxable to you as ordinary income for federal income tax purposes,
except that distributions will be taxed to you at long-term capital gain rates to the extent reported by the Fund as “capital
gain dividends” or “qualified dividend income,” and may also be subject to state or local taxes. Fund distributions may not be
taxable to you if you are investing through a tax-advantaged retirement plan account or are a tax-exempt investor, although you
may be taxed on withdrawals from your tax-advantaged account.
Purchases Through Broker-Dealers and Other Financial Intermediaries
If you purchase Shares through a broker-dealer or other financial intermediary, the Fund and its related companies may pay
the intermediary for the sale of Shares and related services. These payments may create a conflict of interest by influencing the
broker-dealer or other intermediary and your salesperson to recommend Shares over another investment. Ask your salesperson
or visit your financial intermediary’s website for more information.
Let me help you with this. We will also need help with the other discussion board (TOKE).
So what we are doing is removing TOKE from the other discussion board name and applying the ticker here so that we can follow the chart and clarify things for everyone?
TOKE Cambria Cannabis ETF
The Cambria Cannabis ETF seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry. The Fund will target investing in approximately 20 to 50 of the top companies with exposure to the broad cannabis industry based on Cambria’s determination as to their exposure to the industry. The Fund generally expects to invest in companies across a broad market capitalization spectrum of micro-, small-, and mid-capitalization stocks.
FUND PRICES
Premium Discount Chart
Nav
Net Asset Value $15.26
Daily Change $-0.17
Daily Change -1.11%
Volume 4070
Price
Closing Price $15.32
Daily Change $-0.14
Daily Change -0.91%
30-Day Median Bid/Ask Spread 1.3751%
Data as of 12/07/2020
The exchange-traded fund's median bid-ask spread is rounded to the nearest hundredth and computed by (1) identifying the exchange-traded fund's national best bid and national best offer as of the end of each 10 second interval during each trading day of the last 30 calendar days, (2) dividing the difference between each such bid and offer by the midpoint of the national best bid and national best offer, and (3) identifying the median of those values.
PERFORMANCE
Month end returns as of: 11/30/2020
CUMULATIVE
1 Mo. 3 Mo. 6 Mo. Since Inception
Fund NAV 39.18% 22.49% 21.67% -34.66%
Closing Price 39.69% 23.62% 22.86% -34.39%
AVG. ANNUALIZED
1 Yr. 3 Yr. 5 Yr. 10 Yr. Since Inception
Fund NAV 4.78% -26.98%
Closing Price 5.01% -26.76%
Quarter end returns as of 09/30/2020:
AVG. ANNUALIZED
1 Yr. 3 Yr. 5 Yr. 10 Yr. Since Inception
Fund NAV -37.81% -47.34%
Closing Price -38.25% -47.28%
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted.
Cumulative return is the aggregate amount that an investment has gained or lost over time. Annualized return is the average return gained or lost by an investment each year over a given time period. Cambria Funds' NAVs are calculated using prices as of 4:00 PM Eastern Time.
The closing market price is the Mid-Point between the Bid and Ask price as of the close of exchange. Since the Fund's Shares typically do not trade in the secondary market until several days after the Fund's inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.
TOP 10 HOLDINGS
Full Holdings
PERCENTAGE OF NET ASSETS NAME IDENTIFIER SHARES HELD MARKET VALUE
9.18% GW Pharmaceuticals PLC GWPH 12,744 $1,681,443.36
8.03% Aphria Inc. APHA 177,664 $1,469,281.28
6.58% Cash Equivalent 1,203,043 $1,203,043.42
6.55% Canopy Growth Corp. CGC 42,240 $1,198,771.20
6.22% Innovative Industrial Properties Inc. IIPR 7,374 $1,138,914.30
6.00% Greenlane Holdings Inc. GNLN 250,680 $1,097,978.40
5.60% Constellation Brands Inc. STZ 4,836 $1,025,425.44
5.46% Scotts Miracle-Gro Co. SMG 5,756 $998,896.24
4.88% Village Farms International Inc. VFF 84,192 $893,277.12
4.04% British American Tobacco PLC BATS LN 19,392 $739,190.11
Data as of 12/07/2020
Holdings are subject to change
$TOKE
I posted this yesterday but when i looked this morning it shows my post as blank. not sure why.
Cambria Cannabis ETFCboe Consolidated Listings:TOKE
Morningstar rating: Not RatedMiscellaneous Sector
Prospectus
Change fund Symbol lookup
TOKE
Buy
Sell
Set AlertAdd to watch listIncome EstimatorETFs Glossary
$15.49 0.13 (0.85%)Bid
--
Ask
--
B/A Size
--
High
15.68
Low
15.40
Volume
36,161 (Above Avg)
As of December 4, 2020 6:30pm ET
Summary
Performance
Ratings & Risk
Portfolio
Chart
Print All Tabs
Gross Expense Ratio*0.59%
Net Expense Ratio*0.42%
Total Assets$17M
SEC 30 Day Yield (as of 11/30/20 )2.98%
Distribution Yield (TTM)5.11%
Ann. Dividend/Yield$0.5448/3.52%
Ex-Dividend Date9/24/2020
Premium/Discount0.39%
52-Wk Range
7.85 - 16.67
LowHigh
Leveraged ETF Factor100
Fund Inception07/25/2019
Historical Quotes & Splits
Current | 1mo | 3mo | 6mo | 1yrDJIAS&P 500NASDAQView Advanced Chart
About this ETF
The investment seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry.Under normal market conditions, at least 80% of the value of the fund’s net assets (plus borrowings for investment purposes) will be invested in Cannabis Companies. The Advisor generally expects to invest in Cannabis Companies across a broad market capitalization spectrum of micro-, small-, and mid-capitalization stocks.
Trailing Total Returns
Market Return %
(as of 11/30/2020) NAV Return %
(as of 11/30/2020) Market Return %
(as of 09/30/2020) NAV Return %
(as of 09/30/2020)
1-Month +39.37% +39.18% -12.33% -12.39%
3-Month +22.40% +22.49% -9.88% +22.49%
6-Month +22.50% +21.67% +8.88% +12.21%
Year-to-date +5.17% +5.73% -24.67% -24.38%
1-Year +4.73% +4.78% -38.18% -37.81%
3-Year -- -- -- --
5-Year -- -- -- --
10-Year -- -- -- --
Since Inception -26.71% -27.00% -47.06% -47.36%
Inception Date: July 25, 2019
Performance Details
Total return reflects performance without adjusting for sales charges or the effects of taxation, but is adjusted to reflect all actual ongoing fund expenses and assumes reinvestment of dividends and capital gains. If adjusted, sales charges would reduce the performance quoted.
Performance data quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance potential of the product over varying market conditions or economic cycles. Current performance may be higher or lower than the performance data quotes. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
Standardized Returns
Market Return %
(as of 11/30/2020) NAV Return %
(as of 11/30/2020) Market Return %
(as of 09/30/2020) NAV Return %
(as of 09/30/2020)
1-Year +4.73% +4.78% -38.18% -37.81%
5-Year -- -- -- --
10-Year -- -- -- --
Since Inception -26.71% -27.00% -47.06% -47.36%
Inception Date: July 25, 2019
Sector Breakdown
Cyclical 16.05%
Basic Materials 5.92%
Consumer Cyclical 3.50%
Financial Services 0.00%
Real Estate 6.63%
Defensive 83.94%
Consumer Defensive 29.83%
Healthcare 54.11%
Utilities 0.00%
Sensitive 0.00%
Communication Services 0.00%
Energy 0.00%
Industrials 0.00%
Technology 0.00%Portfolio Details
Top 10 Holdings
Company YTD Return
(as of 12/04/2020) % of Assets
* GW Pharmaceuticals PLC ADR +31.49% 9.76%
* Aphria Inc +62.64% 8.14%
* Canopy Growth Corp +35.56% 6.65%
Innovative Industrial Properties Inc Registered Shs +101.54% 6.20%
Greenlane Holdings Inc +38.86% 5.69%
The Scotts Miracle Gro Co A +68.53% 5.53%
Constellation Brands Inc A +12.67% 5.45%
* Village Farms International Inc +72.55% 5.23%
* Cronos Group Inc +12.52% 3.78%
* represents an International company or one without a recognizable symbol.
Portfolio Details
Morningstar Wrap-Up
Morningstar Style Box
Large
Medium
Small
Value Blend Growth
As of 11/30/2020
Risk
Low High
Return
Low High
What's This?
As of 11/30/2020
Reports and Ratings
CFRA
Rating since 11/30/20
View 11/30/20
Fees & Management
Manager Mebane Faber
Manager Start 07/25/2019
Management Fee 0.59%
Expense Ratio 0.42
Carefully consider the investment objectives, risks, charges and expenses before investing. A prospectus, obtained by clicking the Prospectus link, contains this and other important information about an investment company. Read carefully before investing.
*"Gross Expense Ratio" reflects a fund's total annual operating expenses as stated in the fund's prospectus and does not reflect any expense reimbursements or waivers that may exist. This ETF may be subject to expense reimbursements and waivers, and less such reimbursements and waivers may have lower total annual operating expenses (i.e., "Net Expense Ratio") than indicated herein. Please read the fund prospectus carefully to determine the existence of any expense reimbursements or waivers and details on their limits and termination dates.
Performance data quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance potential of the product over varying market conditions or economic cycles. Current performance may be higher or lower than the performance data quotes. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
ETFs are subject to risk similar to those of their underlying securities, including, but not limited to, market, investment, sector, or industry risks, and those regarding short-selling and margin account maintenance. Some ETFs may involve international risk, currency risk, commodity risk, leverage risk, credit risk, and interest rate risk. Performance may be affected by risks associated with nondiversification, including investments in specific countries or sectors. Additional risks may also include, but are not limited to, investments in foreign securities, especially emerging markets, real estate investment trusts (REITs), fixed income, small-capitalization securities, and commodities. Unlike mutual funds, shares of ETFs are not individually redeemable directly with the ETF. Shares are bought and sold at market price, which may be higher or lower than the net asset value (NAV).
Information provided by TD Ameritrade, including without limitation that related to the ETF Market Center, is for general educational and informational purposes only and should not be considered a recommendation or investment advice.
TD Ameritrade receives remuneration from certain ETFs for shareholder, administrative, and/or other services.
No Margin for 30 Days. Certain ETFs will not be immediately marginable at TD Ameritrade through the first 30 days from settlement. For the purposes of calculation the day of settlement is considered Day 1.
PLEASE READ IMPORTANT ADDITIONAL MUTUAL FUND, EXCHANGE-TRADED FUND, AND CLOSED-END FUND RISK DISCLOSURES.
Exchange-Traded Notes (ETNs)
ETNs are not funds and are not registered investment companies. ETNs are not secured debt and most do not provide principal protection. ETNs involve credit risk. The repayment of the principal, any interest, and the payment of any returns at maturity or upon redemption depend on the issuer's ability to pay. The market value of an ETN may be impacted if the issuer's credit rating is downgraded. ETNs may be subject to specific sector or industry risks. Leveraged and inverse ETNs are subject to substantial volatility risk and other unique risks that should be understood before investing. ETNs containing components traded in foreign currencies are subject to foreign exchange risk. ETNs may have call features that allow the issuer to call the ETN. A call right by an issuer may adversely affect the value of the notes.
Sector investing may involve a greater degree of risk than an investment in other funds with broader diversification. Diversification does not eliminate the risk of investment losses.
Leveraged ETPs (exchange-traded products, such a ETFs and ETNs) seek to provide a multiple of the investment returns of a given index or benchmark on a daily basis. Inverse ETPs seek to provide the opposite of the investment returns, also daily, of a given index or benchmark, either in whole or by multiples. Due to the effects of compounding and possible correlation errors, leveraged and inverse ETPs may experience greater losses than one would ordinarily expect. Compounding can also cause a widening differential between the performances of an ETP and its underlying index or benchmark, so that returns over periods longer than one day can differ in amount and direction from the target return of the same period. Consequently, these ETPs may experience losses even in situations where the underlying index or benchmark has performed as hoped. Aggressive investment techniques, such as futures, forward contracts, swap agreements, derivatives, and options, can increase ETP volatility and decrease performance. Leveraged and inverse ETPs are subject to substantial volatility risk and other unique risks that should be understood before investing. Investors holding these ETPs should therefore monitor their positions as frequently as daily.
The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.
Helluva first post
$TOKE
Holdings
10% $GWPH
7% $CGC
6% $IIPR
6% $GNLN
5% $STZ
5% $VFF
Cambria Cannabis ETFCboe Consolidated Listings:$TOKE
Morningstar rating: Not RatedMiscellaneous Sector
Prospectus
Change fund Symbol lookup
TOKE
Buy
Sell
Set AlertAdd to watch listIncome EstimatorETFs Glossary
$15.49 0.13 (0.85%)Bid
--
Ask
--
B/A Size
--
High
15.68
Low
15.40
Volume
36,161 (Above Avg)
As of December 4, 2020 6:30pm ET
Summary
Performance
Ratings & Risk
Portfolio
Chart
Print All Tabs
Gross Expense Ratio*0.59%
Net Expense Ratio*0.42%
Total Assets$17M
SEC 30 Day Yield (as of 11/30/20 )2.98%
Distribution Yield (TTM)5.11%
Ann. Dividend/Yield$0.5448/3.52%
Ex-Dividend Date9/24/2020
Premium/Discount0.39%
52-Wk Range
7.85 - 16.67
LowHigh
Leveraged ETF Factor100
Fund Inception07/25/2019
Historical Quotes & Splits
Current | 1mo | 3mo | 6mo | 1yrDJIAS&P 500NASDAQView Advanced Chart
About this ETF
The investment seeks capital appreciation from investments in the global equity markets that have exposure to the broad cannabis industry.Under normal market conditions, at least 80% of the value of the fund’s net assets (plus borrowings for investment purposes) will be invested in Cannabis Companies. The Advisor generally expects to invest in Cannabis Companies across a broad market capitalization spectrum of micro-, small-, and mid-capitalization stocks.
Trailing Total Returns
Market Return %
(as of 11/30/2020) NAV Return %
(as of 11/30/2020) Market Return %
(as of 09/30/2020) NAV Return %
(as of 09/30/2020)
1-Month +39.37% +39.18% -12.33% -12.39%
3-Month +22.40% +22.49% -9.88% +22.49%
6-Month +22.50% +21.67% +8.88% +12.21%
Year-to-date +5.17% +5.73% -24.67% -24.38%
1-Year +4.73% +4.78% -38.18% -37.81%
3-Year -- -- -- --
5-Year -- -- -- --
10-Year -- -- -- --
Since Inception -26.71% -27.00% -47.06% -47.36%
Inception Date: July 25, 2019
Performance Details
Total return reflects performance without adjusting for sales charges or the effects of taxation, but is adjusted to reflect all actual ongoing fund expenses and assumes reinvestment of dividends and capital gains. If adjusted, sales charges would reduce the performance quoted.
Performance data quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance potential of the product over varying market conditions or economic cycles. Current performance may be higher or lower than the performance data quotes. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
Standardized Returns
Market Return %
(as of 11/30/2020) NAV Return %
(as of 11/30/2020) Market Return %
(as of 09/30/2020) NAV Return %
(as of 09/30/2020)
1-Year +4.73% +4.78% -38.18% -37.81%
5-Year -- -- -- --
10-Year -- -- -- --
Since Inception -26.71% -27.00% -47.06% -47.36%
Inception Date: July 25, 2019
Sector Breakdown
Cyclical 16.05%
Basic Materials 5.92%
Consumer Cyclical 3.50%
Financial Services 0.00%
Real Estate 6.63%
Defensive 83.94%
Consumer Defensive 29.83%
Healthcare 54.11%
Utilities 0.00%
Sensitive 0.00%
Communication Services 0.00%
Energy 0.00%
Industrials 0.00%
Technology 0.00%Portfolio Details
Top 10 Holdings
Company YTD Return
(as of 12/04/2020) % of Assets
* GW Pharmaceuticals PLC ADR +31.49% 9.76%
* Aphria Inc +62.64% 8.14%
* Canopy Growth Corp +35.56% 6.65%
Innovative Industrial Properties Inc Registered Shs +101.54% 6.20%
Greenlane Holdings Inc +38.86% 5.69%
The Scotts Miracle Gro Co A +68.53% 5.53%
Constellation Brands Inc A +12.67% 5.45%
* Village Farms International Inc +72.55% 5.23%
* Cronos Group Inc +12.52% 3.78%
* represents an International company or one without a recognizable symbol.
Portfolio Details
Morningstar Wrap-Up
Morningstar Style Box
Large
Medium
Small
Value Blend Growth
As of 11/30/2020
Risk
Low High
Return
Low High
What's This?
As of 11/30/2020
Reports and Ratings
CFRA
Rating since 11/30/20
View 11/30/20
Fees & Management
Manager Mebane Faber
Manager Start 07/25/2019
Management Fee 0.59%
Expense Ratio 0.42
Carefully consider the investment objectives, risks, charges and expenses before investing. A prospectus, obtained by clicking the Prospectus link, contains this and other important information about an investment company. Read carefully before investing.
*"Gross Expense Ratio" reflects a fund's total annual operating expenses as stated in the fund's prospectus and does not reflect any expense reimbursements or waivers that may exist. This ETF may be subject to expense reimbursements and waivers, and less such reimbursements and waivers may have lower total annual operating expenses (i.e., "Net Expense Ratio") than indicated herein. Please read the fund prospectus carefully to determine the existence of any expense reimbursements or waivers and details on their limits and termination dates.
Performance data quoted represents past performance, is no guarantee of future results, and may not provide an adequate basis for evaluating the performance potential of the product over varying market conditions or economic cycles. Current performance may be higher or lower than the performance data quotes. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost.
ETFs are subject to risk similar to those of their underlying securities, including, but not limited to, market, investment, sector, or industry risks, and those regarding short-selling and margin account maintenance. Some ETFs may involve international risk, currency risk, commodity risk, leverage risk, credit risk, and interest rate risk. Performance may be affected by risks associated with nondiversification, including investments in specific countries or sectors. Additional risks may also include, but are not limited to, investments in foreign securities, especially emerging markets, real estate investment trusts (REITs), fixed income, small-capitalization securities, and commodities. Unlike mutual funds, shares of ETFs are not individually redeemable directly with the ETF. Shares are bought and sold at market price, which may be higher or lower than the net asset value (NAV).
Information provided by TD Ameritrade, including without limitation that related to the ETF Market Center, is for general educational and informational purposes only and should not be considered a recommendation or investment advice.
TD Ameritrade receives remuneration from certain ETFs for shareholder, administrative, and/or other services.
No Margin for 30 Days. Certain ETFs will not be immediately marginable at TD Ameritrade through the first 30 days from settlement. For the purposes of calculation the day of settlement is considered Day 1.
PLEASE READ IMPORTANT ADDITIONAL MUTUAL FUND, EXCHANGE-TRADED FUND, AND CLOSED-END FUND RISK DISCLOSURES.
Exchange-Traded Notes (ETNs)
ETNs are not funds and are not registered investment companies. ETNs are not secured debt and most do not provide principal protection. ETNs involve credit risk. The repayment of the principal, any interest, and the payment of any returns at maturity or upon redemption depend on the issuer's ability to pay. The market value of an ETN may be impacted if the issuer's credit rating is downgraded. ETNs may be subject to specific sector or industry risks. Leveraged and inverse ETNs are subject to substantial volatility risk and other unique risks that should be understood before investing. ETNs containing components traded in foreign currencies are subject to foreign exchange risk. ETNs may have call features that allow the issuer to call the ETN. A call right by an issuer may adversely affect the value of the notes.
Sector investing may involve a greater degree of risk than an investment in other funds with broader diversification. Diversification does not eliminate the risk of investment losses.
Leveraged ETPs (exchange-traded products, such a ETFs and ETNs) seek to provide a multiple of the investment returns of a given index or benchmark on a daily basis. Inverse ETPs seek to provide the opposite of the investment returns, also daily, of a given index or benchmark, either in whole or by multiples. Due to the effects of compounding and possible correlation errors, leveraged and inverse ETPs may experience greater losses than one would ordinarily expect. Compounding can also cause a widening differential between the performances of an ETP and its underlying index or benchmark, so that returns over periods longer than one day can differ in amount and direction from the target return of the same period. Consequently, these ETPs may experience losses even in situations where the underlying index or benchmark has performed as hoped. Aggressive investment techniques, such as futures, forward contracts, swap agreements, derivatives, and options, can increase ETP volatility and decrease performance. Leveraged and inverse ETPs are subject to substantial volatility risk and other unique risks that should be understood before investing. Investors holding these ETPs should therefore monitor their positions as frequently as daily.
The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.
I don’t have time this weekend to work on it.
New board for this ETF, will improve in time
TOKE ticker symbol for Cambria Cannabis
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
27
|
Created
|
12/06/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |